| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | AREI; STF1; STFA |
| WB Predicted band size | 11 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CSTA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PIM2抗体的3篇参考文献及其摘要概括：
1. **文献名称**：**"PIM2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation"**
**作者**：Hu et al. (2007)
**摘要**：研究揭示了PIM2激酶在多发性骨髓瘤中的关键作用，通过磷酸化TSC2调控mTOR通路，促进肿瘤细胞存活。实验使用特异性PIM2抗体检测其表达水平，并验证了靶向PIM2的治疗潜力。
2. **文献名称**：**"Targeting PIM2 in hematologic malignancies through kinase inhibition and degradation"**
**作者**：Gomez et al. (2015)
**摘要**：该研究开发了一种新型PIM2小分子抑制剂，并通过PIM2抗体验证其抑制效果。结果显示，抑制PIM2可诱导白血病细胞凋亡，并显著降低下游信号蛋白的磷酸化水平。
3. **文献名称**：**"PIM2 expression is a prognostic biomarker in acute myeloid leukemia"**
**作者**：Brault et al. (2018)
**摘要**：通过免疫组化和Western blot(使用PIM2抗体)分析急性髓系白血病患者的样本，发现PIM2高表达与不良预后相关，提示其作为治疗靶点的潜在价值。
4. **文献名称**：**"PIM2 kinase regulates apoptosis and autophagy in cancer via Bcl-2 family modulation"**
**作者**：Yang et al. (2021)
**摘要**：研究利用PIM2抗体探究其在实体瘤中的功能，发现PIM2通过调控Bcl-2家族蛋白平衡细胞凋亡和自噬，影响肿瘤耐药性，为联合靶向治疗提供依据。
这些文献均涉及PIM2抗体的实验应用，涵盖其在癌症机制、预后评估及靶向治疗中的研究。
The PIM2 antibody is a research tool targeting the Proviral Integration site for Moloney murine leukemia virus 2 (PIM2) kinase, a serine/threonine kinase belonging to the PIM family (PIM1. PIM2. PIM3). PIM2 plays a role in cell survival, proliferation, and apoptosis regulation by phosphorylating downstream substrates involved in signaling pathways like mTOR, STAT, and NF-κB. It is frequently overexpressed in hematologic malignancies (e.g., lymphoma, myeloma, leukemia) and certain solid tumors, where it promotes oncogenesis and therapy resistance.
PIM2 antibodies are widely used in basic and translational research to study its expression, localization, and function in cancer models, as well as its interplay with other oncogenic pathways. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence. Additionally, PIM2 antibodies support drug development efforts, as PIM2 is explored as a therapeutic target. Small-molecule inhibitors and monoclonal antibodies against PIM2 are under investigation to disrupt its kinase activity or block protein interactions, potentially overcoming resistance to conventional therapies. However, challenges remain in achieving tumor-specific targeting due to PIM2's structural similarity with PIM1/PIM3 and its role in normal immune cells. Research using PIM2 antibodies continues to clarify its pathophysiological roles and therapeutic potential.
×
